Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More

Competitor Analysis: Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More

This Competitive Intelligence report about Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More evaluates the landscape of the next wave of investigational antibodies in development as biosimilars of marketed antibodies in regulated and less regulated markets as of December 2019.

Cancer antibodies Avastin, Herceptin and Rituxan/MabThera and anti-TNF antibodies Remicade, Enbrel and Humira were the targets of the first wave of biosimilar antibody developments. With the approval and launch of first wave biosimilar antibodies in regulated and less regulated markets, biosimilar antibody developers and manufacturers have directed their business activity towards the next wave of possible biosimilar antibodies.

The coming wave of patent expiries and loss of market exclusivity in the US and in the European Union has spurred the development of biosimilar antibodies for ophthalmic, metabolic, anti-inflammatory and anti-autoimmune antibodies. While developers in regulated markets focus their activity on those marketed antibodies with patent expiration and loss of market protection until 2025, developers for less regulated markets are already looking beyond the year 2025.

This report evaluates the competitive situation of biosimilar antibody developments in regulated and less regulated markets including

• Lucentis
• Eylea
• Prolia/XGEVA
• Xolair
• Stelara
• Soliris
• Erbitux
• Perjeta
• Synagis
• Yervoy
• Cimzia
• (Ro)Actemra
• Simponi
• Orencia
• Tysabri
• Ilaris
• Opdivo
• Keytruda
• Tecentriq
• Cyramza
• Cosentyx
• Darzalex
• Entyvio

The report provides an overview of the year of the first approval in the US and the EU and global sales in 2018 of these marketed antibodies.

This report includes a compilation of currently active projects in research and development of further biosimilar antibodies. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.